Ziskind A A
Cardiac Unit, Massachusetts General Hospital, Boston 02114.
Postgrad Med. 1988 Sep 1;84(3):73-6. doi: 10.1080/00325481.1988.11700397.
Transdermal scopolamine (Transderm-Scop) is being increasingly used for effective prophylaxis of motion sickness. It is reported to have a lower incidence of CNS side effects than orally administered scopolamine. Although uncommon, such side effects occur more often in the elderly, in those with preexisting psychiatric disease, and in patients concurrently taking other medications with anticholinergic activity. Correct diagnosis may be delayed by the occult location of the delivery system, delayed onset of symptoms, prolonged action, absence of peripheral manifestations, and negative toxicologic screening tests. Treatment is usually supportive. Physostigmine should be reserved for the treatment of severe symptoms.
透皮东莨菪碱（Transderm-Scop）越来越多地用于有效预防晕动病。据报道，与口服东莨菪碱相比，其中枢神经系统副作用的发生率较低。虽然这种副作用不常见，但在老年人、已有精神疾病的患者以及同时服用其他具有抗胆碱能活性药物的患者中更常发生。给药系统位置隐匿、症状出现延迟、作用时间延长、缺乏外周表现以及毒理学筛查试验呈阴性，可能会延误正确诊断。治疗通常是支持性的。毒扁豆碱应留作治疗严重症状之用。
